Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
Public ClinicalTrials.gov record NCT04074746. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
Study identification
- NCT ID
- NCT04074746
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 45 participants
Conditions and interventions
Conditions
- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Classic Hodgkin Lymphoma
- Recurrent Mycosis Fungoides
- Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Refractory Anaplastic Large Cell Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Refractory Mycosis Fungoides
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
- Anti-CD30/CD16A Monoclonal Antibody AFM13 Biological
- Cyclophosphamide Drug
- Fludarabine Drug
- Fludarabine Phosphate Drug
- Genetically Engineered Lymphocyte Therapy Biological
Biological · Drug
Eligibility (public fields only)
- Age range
- 15 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 17, 2020
- Primary completion
- Sep 21, 2025
- Completion
- Sep 21, 2025
- Last update posted
- Sep 29, 2025
2020 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04074746, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04074746 live on ClinicalTrials.gov.